These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27404493)

  • 1. CFH Y402H and VEGF Polymorphisms and Anti-VEGF Treatment Response in Exudative Age-Related Macular Degeneration.
    Kepez Yildiz B; Ozdek S; Ergun MA; Ergun S; Yaylacioglu Tuncay F; Elbeg S
    Ophthalmic Res; 2016; 56(3):132-8. PubMed ID: 27404493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of the CFH Y402H Polymorphism with the 1-Year Response of Exudative AMD to Intravitreal Anti-VEGF Treatment in the Brazilian Population.
    Medina FMC; Motta AALD; Takahashi WY; Carricondo PC; Motta MMDS; Melo MB; Vasconcellos JPC
    Ophthalmic Res; 2019; 61(3):168-173. PubMed ID: 28641277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration.
    Nischler C; Oberkofler H; Ortner C; Paikl D; Riha W; Lang N; Patsch W; Egger SF
    Acta Ophthalmol; 2011 Jun; 89(4):e344-9. PubMed ID: 21232084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Response to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment of Age-Related Macular Degeneration.
    Shah AR; Williams S; Baumal CR; Rosner B; Duker JS; Seddon JM
    Am J Ophthalmol; 2016 Mar; 163():154-166.e8. PubMed ID: 26705092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Variants of Complement Factor H Y402H (rs1061170), C2 R102G (rs2230199), and C3 E318D (rs9332739) and Response to Intravitreal Anti-VEGF Treatment in Patients with Exudative Age-Related Macular Degeneration.
    Kubicka-Trząska A; Żuber-Łaskawiec K; Dziedzina S; Sanak M; Romanowska-Dixon B; Karska-Basta I
    Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630075
    [No Abstract]   [Full Text] [Related]  

  • 6. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab.
    Brantley MA; Fang AM; King JM; Tewari A; Kymes SM; Shiels A
    Ophthalmology; 2007 Dec; 114(12):2168-73. PubMed ID: 18054635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration.
    Cobos E; Recalde S; Anter J; Hernandez-Sanchez M; Barreales C; Olavarrieta L; Valverde A; Suarez-Figueroa M; Cruz F; Abraldes M; Pérez-Pérez J; Fernández-Robredo P; Arias L; García-Layana A
    Acta Ophthalmol; 2018 Mar; 96(2):e201-e212. PubMed ID: 28926193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration.
    Boltz A; Ruiß M; Jonas JB; Tao Y; Rensch F; Weger M; Garhöfer G; Frantal S; El-Shabrawi Y; Schmetterer L
    Ophthalmology; 2012 Aug; 119(8):1615-20. PubMed ID: 22521084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of genetic base in the treatment of age-related macular degeneration.
    Gourgouli K; Gourgouli I; Tsaousis G; Spai S; Niskopoulou M; Efthimiopoulos S; Lamnissou K
    Int Ophthalmol; 2020 Apr; 40(4):985-997. PubMed ID: 31916060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Single-Nucleotide Polymorphisms in Age-Related Macular Degeneration With Pseudodrusen: Secondary Analysis of Data From the Comparison of AMD Treatments Trials.
    Lin LY; Zhou Q; Hagstrom S; Maguire MG; Daniel E; Grunwald JE; Martin DF; Ying GS;
    JAMA Ophthalmol; 2018 Jun; 136(6):682-688. PubMed ID: 29801032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Association between Y402H, E318D and R102G polymorphisms of complement proteins genes and the response to intravitreal anti-VEGF treatment in patients with neovascular age-related macular degeneration].
    Kubicka-Trząska A; Karska-Basta I; Kobylarz J; Dziedzina S; Sanak M; Romanowska-Dixon B
    Klin Oczna; 2016; 118(2):114-21. PubMed ID: 29912491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin 8 promoter polymorphism predicts the initial response to bevacizumab treatment for exudative age-related macular degeneration.
    Hautamäki A; Kivioja J; Vavuli S; Kakko S; Savolainen ER; Savolainen MJ; Liinamaa MJ; Seitsonen S; Onkamo P; Järvelä I; Immonen I
    Retina; 2013 Oct; 33(9):1815-27. PubMed ID: 23584701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suggestive association between PLA2G12A single nucleotide polymorphism rs2285714 and response to anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration.
    Wang VM; Rosen RB; Meyerle CB; Kurup SK; Ardeljan D; Agron E; Tai K; Pomykala M; Chew EY; Chan CC; Tuo J
    Mol Vis; 2012; 18():2578-85. PubMed ID: 23112570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Y402H polymorphism in complement factor H and age-related macular degeneration in the Tunisian population.
    Habibi I; Sfar I; Kort F; Aounallah-Skhiri H; Chebil A; Chouchene I; Bouraoui R; Limaiem R; Largheche L; Jendoubi-Ayed S; Makhlouf M; Ben Abdallah T; Ayed K; El Matri L; Gorgi Y
    Ophthalmic Res; 2013; 49(4):177-84. PubMed ID: 23306536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Risk Alleles in CFH, C3, and VEGFA on the Response to Intravitreal Bevacizumab in Tunisian Patients with Neovascular Age-related Macular Degeneration.
    Habibi I; Kort F; Sfar I; Chebil A; Bouraoui R; Ben Abdallah T; Gorgi Y; El Matri L
    Klin Monbl Augenheilkd; 2016 Apr; 233(4):465-70. PubMed ID: 27116510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic Effect of Complement Factor H Gene Polymorphism in Response to the Initial Intravitreal Injection of Bevacizumab for Wet Age-Related Macular Degeneration.
    Medina FM; Alves Lopes da Motta A; Takahashi WY; Carricondo PC; Dos Santos Motta MM; Melo MB; Vasconcellos JP
    Ophthalmic Res; 2015; 54(4):169-74. PubMed ID: 26439641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-reactive protein and complement factor H polymorphism interaction in advanced exudative age-related macular degeneration.
    Soheilian R; Jabbarpour Bonyadi MH; Moein H; Babanejad M; Ramezani A; Yaseri M; Soheilian M
    Int Ophthalmol; 2017 Oct; 37(5):1161-1168. PubMed ID: 27778189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.
    Abedi F; Wickremasinghe S; Richardson AJ; Islam AF; Guymer RH; Baird PN
    Ophthalmology; 2013 Aug; 120(8):1641-8. PubMed ID: 23582991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of the Complement Factor H Y402H Polymorphism and Response to Anti-Vascular Endothelial Growth Factor Treatment in Age-Related Macular Degeneration: An Updated Meta-Analysis.
    Roshanshad A; Moosavi SA; Arevalo JF
    Ophthalmic Res; 2024; 67(1):358-386. PubMed ID: 38754401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration.
    Immonen I; Seitsonen S; Tommila P; Kangas-Kontio T; Kakko S; Savolainen ER; Savolainen MJ; Liinamaa MJ
    Ophthalmology; 2010 Jan; 117(1):103-8. PubMed ID: 19896188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.